GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Entera Bio Ltd (FRA:5DT) » Definitions » Cash Flow for Lease Financing

Entera Bio (FRA:5DT) Cash Flow for Lease Financing : €0.00 Mil (TTM As of Mar. 2024)


View and export this data going back to 2020. Start your Free Trial

What is Entera Bio Cash Flow for Lease Financing?

Entera Bio's Cash Flow for Lease Financing for the three months ended in Mar. 2024 was €0.00 Mil. Entera Bio's Cash Flow for Lease Financing for the trailing twelve months (TTM) ended in Mar. 2024 was €0.00 Mil.

Compared with last quarter (€0.00 Mil in Dec. 2023 ), Entera Bio's Cash Flow for Lease Financing remained the same in Mar. 2024 (€0.00 Mil).

Entera Bio Cash Flow for Lease Financing Historical Data

The historical data trend for Entera Bio's Cash Flow for Lease Financing can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Entera Bio Cash Flow for Lease Financing Chart

Entera Bio Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cash Flow for Lease Financing
Get a 7-Day Free Trial Premium Member Only - - - - -

Entera Bio Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Cash Flow for Lease Financing Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Entera Bio Cash Flow for Lease Financing Calculation

Cash Flow for Lease Financing is change in cash flow resulting from increase or decrease in lease financing.


Cash Flow for Lease Financing for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was €0.00 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Entera Bio Cash Flow for Lease Financing Related Terms

Thank you for viewing the detailed overview of Entera Bio's Cash Flow for Lease Financing provided by GuruFocus.com. Please click on the following links to see related term pages.

Entera Bio (FRA:5DT) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Entera Bio Ltd (FRA:5DT) » Definitions » Cash Flow for Lease Financing
Comparable Companies
INDP AZTR MYMD IGXT ONCT PLUR AKTX IGC CBIO ICU OCSE:NOVO B VRTX REGN ASX:CSL SGEN XKRX:207940 MRNA HKSE:02269 XBRU:ARGX BNTX
Traded in Other Exchanges
ENTX:USA
Address
Minrav Building - Fifth Floor, Kiryat Hadassah, Jerusalem, ISR, 9112002
Website
https://www.enterabio.com
Entera Bio Ltd is a clinical-stage biopharmaceutical company engaged in the development of orally delivered macromolecule therapeutics, including peptides and therapeutic proteins. The company focuses on underserved, chronic medical conditions where oral administration of a mini tablet peptide or peptide replacement therapy has the potential to significantly shift a treatment paradigm. Its product candidates are; EB613 for the treatment of osteoporosis and EB612 for the treatment of hypoparathyroidism are first-in-class mini tablet formulations of synthetic human PTH (1-34) (teriparatide), designed to have differing pharmacokinetic, or PK, profiles.

Entera Bio (FRA:5DT) Headlines

No Headlines